|
|
|
|
|
|
|
|
|
27.05.26 - 08:33
|
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from ten presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain....
|
|
|
13.05.26 - 08:09
|
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/....
|
|
|
|
|
24.04.26 - 14:03
|
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 10,700 shares of the Company's stock (the “Inducement Grant”) to newly hired employees on April 22, 2026 (the “Grant Date”), in connection with the commencement of employment....
|
|
|
17.04.26 - 12:25
|
Aligos and Xiamen Amoytop sign deal for HBV therapy (PBR)
|
|
|
This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by
The post Aligos and Xiamen Amoytop sign deal for HBV therapy appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
16.04.26 - 12:03
|
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has entered into an exclusive license agreement to develop and commercialize pevifoscorvir sodium with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”) in Greater China, which includes Mainland China, Taiwan, Hong Kong, and Macau for chronic hepatitis B virus (HBV) infection....
|
|
|
14.04.26 - 22:06
|
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the first interim analysis results of the Phase 2 B-SUPREME study of pevifoscorvir sodium in participants with chronic hepatitis B virus (HBV) infection for the Part 2a (HBeAg- cohort) where the independent Data Safety Monitoring Review Board (DSMB) has recommended continuation of the study with an increase in sample size for this cohort in order to optimize statistical powering; futility criteria for the cohort was not met. Additionally, Aligos announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to pevifoscorvir sodium, a potential best/first-in-class capsid assembly modulator (CAM-E) under investigation for the treatment of chronic hepatitis B virus (HBV) infection....
|
|
|
|
|
|
|
|
|
30.01.26 - 14:03
|
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 81,100 shares of the Company's stock (the “Inducement Grant”) to newly hired employees on January 29, 2026 (the “Grant Date”), in connection with the commencement of employment....
|
|
|
|
|
|
|
|
|
12.12.25 - 14:03
|
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 14,100 shares of the Company's stock (the “Inducement Grant”) to newly hired employees on December 9, 2025 (the “Grant Date”), in connection with the commencement of employment....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
